Request Information
Request Information
Feb 13 2019
Forbes recently featured Auris in an article about Johnson & Johnson's $3.5 billion all-cash acquisition of the company. In the deal, Auris is also eligible to receive up to $2.35 billion in additional milestone payments. This deal will boost J&J's plan to expand its robotics program.
Continue ReadingFeb 13 2019
Auris was featured on MedCity News, an online publication covering the business of healthcare innovation, for its recent acquisition by Johnson & Johnson. Seeking to expand their digital surgery business, J&J paid $3.4 billion in cash to acquire Auris. Auris is also eligible to receive up to $2.3 billion in additional payments from J&J after hitting predetermined milestones. Auris will be included as part of Ethicon, J&J's medical device subsidiary.
Continue ReadingFeb 13 2019
Peter Hébert, co-founder and Managing Partner of Lux, wrote an article about Auris that was published in Medium. Believing strongly in Auris's mission, Lux co-led Auris Health's Series A financing in 2012 and has invested nearly $50 million since the company's inception. On the heels of Auris's recent acquisition by Johnson & Johnson, Hébert's article highlights Auris's mission and how J&J will help to further that mission.
Continue ReadingFeb 13 2019
Johnson & Johnson's $3.4 billion all-cash purchase of Auris Health was featured in Xconomy, a publication that reports on the latest in business, life sciences, and technology.
Continue ReadingFeb 13 2019
FierceBiotech featured Auris in an article about Johnson & Johnson's $3.4 billion all-cash agreement to acquire Auris Health. Auris could receive up to $2.35 billion in additional payments by hitting certain milestones. FierceBiotech previously named Auris among their "Fierce 15" in medtech in 2017.
Continue ReadingFeb 13 2019
Johnson & Johnson's deal to buy Auris Health Inc. could have major impact across the entire med-tech industry, according to the Wall Street Journal. At $3.4 billion, the cash deal is the largest acquisition of a venture-backed medical device company to date.
Continue ReadingFeb 13 2019
Auris was featured in an article on TechCrunch, an online publication that covers the tech industry, about the recent announcement that Johnson & Johnson will acquire Auris for $3.4 billion in cash.
Continue ReadingJan 22 2019
Many come for the entertainment, others come for innovation. The Monarch™ Platform has been announced as a finalist for SXSW’s Interactive Innovation Award. Auris Health, creators of the first-of-its-kind technology, and Fjord, Accenture Interactive’s global design and innovation consultancy involved in the development of the system, are being honored for their joint innovation and efforts to revolutionize endoscopy.
Continue ReadingDec 03 2018
According to Forbes, healthcare startups raised $28.8 billion in venture capital funding from January 2018 through November 2018. This is up 50% from last year over the same time frame, according to an analysis conducted for Forbes by Pitchbook.
Continue ReadingNov 30 2018
Auris was featured in an article in BioWorld MedTech, a news organization covering the medical technology industry. The article discusses how Auris recently raised $220 million in funding to back commercialization and development efforts for the Monarch Platform.
Continue ReadingBronchoscopy:
Complications from bronchoscopy are rare and most often minor, but if they occur, may include breathing difficulty, vocal cord spasm, hoarseness, slight fever, vomiting, dizziness, bronchial spasm, infection, low blood oxygen, bleeding from biopsied site, or an allergic reaction to medications. Only rarely do patients experience other more serious complications (for example, collapsed lung, respiratory failure, heart attack and/or cardiac arrhythmia).
Urology:
Adverse effects from both Mini-PCNL and Ureteroscopy include pain, urinary tract infection, fever, hematuria (presence of blood in urine), exposure to low levels of radiation, retained or residual stones.
Adverse effects from ureteroscopy may include pain, perforation or injury to the ureter, resulting in extravasation of fluid and urine (urinoma), stricture of the ureter with risk of subsequent obstruction (hydronephrosis needing further repair), rare avulsion of the ureter, urinary blood clots, residual stones.
PCNL access may result in minor and major adverse effects. Minor effects include fever and nephrostomy leak. Major adverse effects may include injuries to pleura, liver, spleen, large vessels with related bleeding, gallbladder, duodenum, jejunum, colon with related cutaneous fistula, fever, pain, ileus, elevated counts.
Major adverse effects related to stone removal may include infection and urosepsis, intravascular fluid overload, extravasation of fluid, and post percutaneous nephrolithotomy bleeding.